

CORPORATE PROFILE

Sino Biopharmaceutical Limited (the “Company”), together with its subsidiaries, an associate and jointly-controlled entities (the “Group”), is an integrated pharmaceutical enterprise. Applying advanced biotechnology and modernized Chinese medicinal technology, the Group researches, develops, manufactures and markets a vast array of health enhancing biopharmaceuticals, modernized Chinese medicines and chemical medicines. The Group has also strategically expanded into the energy chemical industry. Through its wholly-owned subsidiary Chia Tai Refined Chemical Industry Limited (“CTRC”), the Group would establish a joint venture engaging in the high growth business of refining of coal into methanol to low carbon olefin (MTO) products in Yulin City, Shaanxi Province, the People's Republic of China (the “PRC” or “China”).

The Group's pharmaceutical products can be grouped under two major therapeutic categories: cardio-cerebral diseases and hepatitis. It also actively develops medicines for treating tumors, analgesia, respiratory system diseases, diabetes and digestive system diseases to meet the increasing demands of the market, medical practitioners and patients.

Principal products:

Cardio-cerebral medicines: Kaishi (Alprostadi) injections, Spring (Purarin) injections

Hepatitis medicines: Ganlixin (Diammonium Glycyrrhizinate) injections and capsules, Tianqingfuxin (Marine) injections and capsules

Oncology medicines: Tianqingyitai (Zolebrionate Acid) injections

Analgesic medicines: Kaifen (Flurbiprofen Axetil) injections

New Key products with great potential include:

Hepatitis medicines: Tianqingganmei (Magnesium Isoglycyrrhizinate) injections, Tianqingganping (Diammonium Glycyrrhizinate) enteric capsules, Mingzheng (Adefovir Dipivoxil) capsules

Cardio-cerebral medicines: Tianqinggan (Glycerin and Fructose) injections, Tianqingning (Hydroxyethylstarch 130) injections

Oncology medicines: Renyi (Pamidronate Disodium) injections

Respiratory medicines: Tianqingzhengshu (Loratadine) tablets

Diabetic medicines: Taibai (Metformin Hydrochloride) sustained release tablets, Beijia (Nateglinide) tablets



Forbes Award



Gold Medal in “The Third Chinese International Patented and Famous Brands Exhibition”



Postdoctoral Programme

CORPORATE PROFILE

The medicines which have received Good Manufacturing Practice (“GMP”) certifications issued by the State Food and Drug Administration (“SFDA”) of the PRC are in the following dosage forms: large volume injections, small volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines and granulated medicines. The Group also received the GMP Certification for Health Food in capsules from the Department of Health of Jiangsu Province.

The Group’s principal subsidiary-Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. (“JCTT”) and the jointly-controlled entity, Beijing Tide Pharmaceutical Co., Ltd. (“Beijing Tide”) have both been designated “High and New Technology Enterprises” and “Foreign Invested Advanced Technology Enterprises”. Beijing Tide also received the “Key New and High Technology Enterprise” certificate from the Torch High Technology Industry Development Center of the Ministry of Science and Technology of the PRC in June 2006. Beijing Chia Tai Green Continent Pharmaceutical Co. Ltd. (“CTGC”), another subsidiary of the Group, was also hailed as a “High and New Technology Enterprise”.

The research center of JCTT was recognized as the “Postdoctoral Research & Development Institute” by the PRC’s Ministry of Personnel. It is the country’s unique “New Hepatitis Medicine Research Center”.

The Group’s website: <http://www.sinobiopharm.com>

Stock Code: 1177

GROUP STRUCTURE

FIG.1.1

